Product Description
OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/15242254/)
Mechanisms of Action: cGAMP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Melanoma|Crohn Disease|Renal Cell Carcinoma|Prostate Cancer
Phase 1: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| OSI-461-010 | P1 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
None |
2019-03-21 |
||
| OSI-461-005 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
None |
2019-03-21 |
||
| OSI-461-013 | P2 |
Terminated |
Melanoma |
None |
2019-03-21 |
Treatments |
|
| OSI-461-012 | P2 |
Completed |
Crohn Disease |
None |
2019-03-21 |
Treatments |
|
| OSI-461-003 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
||
| OSI-461-006 | P2 |
Completed |
Prostate Cancer |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|